Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Keros Therapeutics, Inc.NASDAQ: KROS
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) turns negative
Q1 FY2026 EPS (Basic) was -$0.64, compared with $3.66 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.44.
Context
- EPS (Basic) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 3 analysts of -$3.64 (-255.6%) for the fiscal year ending Dec 2026, a slowdown from the +146.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.64+25.6% QoQ
- Last fiscal yearDec 2025
- $2.34+146.8% YoY
- LTMMar 2026
- -$2.44-1120.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -117.5% | -76.3% | +41.2 pp |
| 1 year | +146.8% | -255.6% | -402.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- 2.34 USD
- Year-over-year change
- +146.8%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.34 | +146.8% |
| FY2024 | 2024-12-31 | (5.00) | +3.8% |
| FY2023 | 2023-12-31 | (5.20) | -25.3% |
| FY2022 | 2022-12-31 | (4.15) | -64.7% |
| FY2021 | 2021-12-31 | (2.52) | — |
EPS (Basic) vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 EPS (Basic) of -$2.44 is the 7th highest of the 10 companies compared; the peer median is -$0.83.
- Its year-over-year change of -1120.0% is the lowest of 10, against a peer median of +9.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $20.07 | +855.7% | — | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $0.23 | +31.5% | — |
| LTM Mar 2026 | -$0.36 | -172.2% | — | |
| LTM Mar 2026 | -$0.55 | +14.1% | — | |
| LTM Mar 2026 | -$0.83 | +9.8% | — | |
| LTM Mar 2026 | -$2.02 | +2.4% | — | |
| LTM Mar 2026 | -$2.44 | -1120.0% | — | |
| LTM Mar 2026 | -$2.5 | +30.0% | — | |
| LTM Mar 2026 | -$3.88 | -68.7% | — | |
| LTM Mar 2026 | -$5.6 | -80.1% | — | |
| Peer median (excluding KROS) | -$0.83 | +9.8% | — | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.1M | 0 | 151K | 3.55M | 244.06M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.51M |
| Gross Profit | 20.1M | 0 | 151K | 3.55M | 242.55M |
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 99.4% |
| Research & Development | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
| Selling, General & Admin | 21.33M | 27.53M | 34.83M | 40.75M | 46.85M |
| Operating Expenses | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| EBITDA | (56.35M) | (104M) | (152.18M) | (185.82M) | 93.41M |
| EBITDA Margin | -280.4% | — | -100779.5% | -5234.5% | 38.3% |
| Operating Income | (56.37M) | (114.79M) | (169.94M) | (210.83M) | 70.62M |
| Operating Margin | -280.5% | — | -112543.7% | -5939.0% | 28.9% |
| Interest Income | 0 | 1K | 0 | 0 | 0 |
| Interest Expense | 4K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (360K) | 10.11M | 16.95M | 23.78M | 21.27M |
| Income Before Tax | (56.73M) | (104.68M) | (152.99M) | (187.05M) | 91.9M |
| Pre-Tax Margin | -282.3% | — | -101319.2% | -5269.1% | 37.7% |
| Income Tax Expense | 2.01M | 0 | 0 | 300K | 4.88M |
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Net Margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (Basic) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 |
| EPS (Diluted) | (2.52) | (4.15) | (5.20) | (5.00) | 2.30 |
| Weighted Avg Shares | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M |
| Weighted Avg Shares (Diluted) | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.